![]() |
DCIS patients receiving anastrozole reported symptoms different from those receiving
Both groups reported similar quality of life. Analysis of patient-reported outcomes (PRO), a secondary endpoint of the phase III, NSABP B-35 clinical trial, in which anastrazole and tamoxifen were...
More... |
| All times are GMT -7. The time now is 03:40 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021